Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

15 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Expression Profiles in Skeletal Muscle and Liver of Type 2 Diabetes Rats

ABSTRACT: Analyzing changes in gene expression in liver and skeletal muscle from streptozotocin-diabetic rats. From the 9,929 expressed genes across the genome, 1,305 and 997 differentially expressed genes (DEGs, P < 0.01) were identified in comparisons of skeletal muscle and liver, respectively. Interestingly, large numbers of DEGs (200) were common to both comparisons, which was clearly more than the predicted number (131 genes, P < 10−4). Further interpretation of gene ontology used three over-representation analysis software (WebGestalt, Expander and GATHER). All the tools detected one KEGG pathway (MAPK signaling) and two GO biological processes (response to stress and cell death), with enrichment of DEGs in both tissues. In addition, PPI (protein-protein interaction) networks constructed using human homologs not only revealed the tendency of DEGs to form a highly connected module, but also suggested a “hub” role of MAPK related genes (such as MAPK14) in the pathogenesis of T2D. Total RNA obtained from liver and skeletal muscle of streptozotocin-diabetic rats and controls, respectivly.

ORGANISM(S): Rattus norvegicus

SUBMITTER: xl tang

PROVIDER: E-GEOD-41832 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Gene Expression Profiles in Skeletal Muscle and Liver of Type 2 Diabetes Rats

Project description:Analyzing changes in gene expression in liver and skeletal muscle from streptozotocin-diabetic rats. From the 9,929 expressed genes across the genome, 1,305 and 997 differentially expressed genes (DEGs, P < 0.01) were identified in comparisons of skeletal muscle and liver, respectively. Interestingly, large numbers of DEGs (200) were common to both comparisons, which was clearly more than the predicted number (131 genes, P < 10−4). Further interpretation of gene ontology used three over-representation analysis software (WebGestalt, Expander and GATHER). All the tools detected one KEGG pathway (MAPK signaling) and two GO biological processes (response to stress and cell death), with enrichment of DEGs in both tissues. In addition, PPI (protein-protein interaction) networks constructed using human homologs not only revealed the tendency of DEGs to form a highly connected module, but also suggested a “hub” role of MAPK related genes (such as MAPK14) in the pathogenesis of T2D.

2012-10-27 | GSE41832 | GEO

Transcription profiling of mouse skeletal muscle in streptozotocin diabetes with or without insulin treatment

Project description:Metabolic abnormalities underlying diabetes are primarily the result of the lack of adequate insulin action and the associated changes in protein phosphorylation and gene expression. Affymetrix oligonucleotide microarrays were used to study the changes in the transcriptional program of mouse skeletal muscle in insulin-deficient diabetes. Mice which were made diabetic by streptozotocin treatment were compared to controls. Also, the reversibility of these changes was ascertained by treating a subset of the diabetic mice with insulin.

2007-04-05 | E-CBIL-25 | biostudies-arrayexpress

Transcription profiling of rat treated with streptozotocin or buffer alone at age of 8 weeks, diaphragm muscle

Project description:8 week old rats injected with streptozotocin or buffer alone at age of 8 weeks, diaphragm muscle obtained at age of 12 weeks (thus animals were diabetic for 4 weeks) Experiment Overall Design: Three control rats (normal diaphragm #1, 2, 3) Experiment Overall Design: Three diabetic rats (diabetic diaphragm #1, 2, 3)

2009-11-28 | E-GEOD-4653 | biostudies-arrayexpress

Differential gene expression in liver tissues of streptozotocin-induced diabetic rats in response to resveratrol treatment

Project description:This study was conducted to elucidate the genome-wide gene expression profile in streptozotocin induced diabetic liver tissues in response to resveratrol treatment.

2015-03-11 | E-MTAB-3293 | biostudies-arrayexpress

Comparative expression profiling identifies differential roles for Myogenin and p38M-NM-1 MAPK signaling in myogenesis

Project description:Mitogen activated protein kinase (MAPK) signaling regulates differentiation of many cell types. During myogenesis in particular, p38a MAPK (MAPK14) phosphorylates multiple transcriptional regulators to modulate muscle-specific gene expression. Among the p38a MAPK modulated genes is the muscle-specific transcriptional regulator Myogenin (Myog) that is also essential to complete the muscle differentiation program, and while it is known that both p38a MAPK and Myog are critically required for myogenesis, the individual contribution of each of these proteins is poorly defined. Here we show that Myog expression (in the absence of p38a MAPK signaling) is sufficient to establish expression of many late markers of muscle differentiation and to mediate cell migration. However, Myog expression alone did not led to the formation of multinucleated muscle cells, highlighting a critical role for p38a MAPK in myoblast fusion. Using comparative microarray analysis we identified p38a MAPK-dependent genes that are not regulated by Myog We generated a stable C2C12-derived cell line (C2i-Myog) that expresses a Doxycycline (Dox)-inducible cDNA encoding Flag-tagged Myog. In this system, the chemical induction of exogenous Myog (Dox) combined with the pharmacological inhibition of p38a/b MAPK signaling by SB203580 (SB) would allow us to assess the functional contribution of these two pathways during myogenesis

2012-08-01 | E-GEOD-25763 | biostudies-arrayexpress

Comparative expression profiling identifies differential roles for Myogenin and p38α MAPK signaling in myogenesis

2012-08-02 | GSE25763 | GEO

Gene expression data for liver, adipose, and skeletal muscle tissues of MKR and Healthy mice.

Project description:MKR mice is a Type 2 Diabetic mice, which was created by expressing mutation in IGF1 receptor in the skeletal muscle, and is widely used in diabetes research. Gene expression differences between MKR mice and Healthy (Wild type) mice are poorly understood. We used microarrays to detail the differences between gene expression in liver, fat, and skeletal muscle of MKR and Healthy mice.

2013-10-30 | GSE51866 | GEO

Diaphragm in Diabetes

2009-11-13 | GSE4653 | GEO

Transcription profiling of rat rear leg muscle from normal and diabetic subjects treated with vanadyl sulfate

Project description:RNA was obtained from rear leg muscle of normal and diabetic rats in the presence and absence of oral treatment with vanadyl sulfate. Diabetes was induced with streptozotocin and expression profiles were determined using Affymetrix Rat Genechip U34A. The effect of treatment and disease on gene expression was examined. Experiment Overall Design: 4 groups (normal, diabetic, normal treated with vanadyl sulfate and diabetic treated with vanadyl sulfate) with 5 replicates in each group were analyzed. Experiment Overall Design: PMID:16403228 discusses 2 groups (normal, diabetic). Experiment Overall Design: PMID:16684804 discusses all four groups.

2007-11-06 | E-GEOD-3068 | biostudies-arrayexpress

A novel insulin receptor-binding protein enhances glucose uptake and glucose clearance in vitro and in vivo through triggering insulin receptor signaling pathway

Project description:In this study, a novel IR-binding protein (IRBP) from Momordica charantia, named as mcIRBP, was identified by analyzing the physical and functional interactions between mcIRBP and IR. The hypoglycemic effect and mechanism of mcIRBP were further evaluated in normal and streptozotocin-induced diabetic mice. Normal and diabetic mice were treated without or with mcIRBP and RNAs from muscle tissues were extracted for microarray analysis. Number of replicate was three.

2016-06-25 | E-GEOD-48274 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data